Expression of IL-2 by mature B cells, but not BM-localized IL-2, drives the ILC2-eosinophil circuit. (A) BM cellularity of 4–6-wk-old Cd19creRosaIL-2 mice and littermate controls. n = 9–11. (B) Frequency of eosinophils in the BM. n = 6–14. (C) Correlation between clusters in Fig. 8 D. WT:RosaIL-2 indicates whether correlation is higher or lower in WT relative to Cd19cre RosaIL-2. (D) Representative gating and frequency of myeloid progenitors (MP; lineage−Sca-1−c-kit+) cells in the BM, pregated on CD45+lineage−. n = 3. (E) Representative gating and frequency of GMPs (granulocyte-monocyte progenitors) in the BM (pregated from MP gate). n = 3. (F) Serum IL-5 in mixed WT/CD4creRosaIL-2 BM chimeras as generated in Fig. 5 A. (G) IL-5 expression among cellular lineages in the BM. n = 6–9. pDC, plasmacytoid DC. (H) Frequency of GATA3+ ILC2 among total ILCs in BM. n = 4–6. (I) Frequency of ILC2 in BM. n = 4–6. (J) Frequency of eosinophils in the BM of mice treated with anti−IL-5 neutralizing antibody. n = 3–8 mice. (K) Representative tSNE of high-parameter flow cytometry data from 4–6-wk-old CD23creRosaIL-2 mice and littermate control splenic viable cells and average frequency of each cluster per mouse. (L) Representative gating and frequency of eosinophils in spleen and BM. n = 6. SSC, side scatter. (M) Frequency of GATA3+ ILC2 among total ILCs in spleen. (N) Frequency of ILC2 in spleen. (O) Representative tSNE of high-parameter flow cytometry data from 4–6-wk-old OsxcreRosaIL-2 and control splenic viable cells and average frequency of each cluster per mouse. (P) Frequency of eosinophils in spleen and BM. n = 3. (Q) Frequency of GATA3+ ILC2 among total ILCs in spleen. (R) Frequency of ILC2 in spleen. Significance was tested by unpaired t test (A, D, E, H, I, L–N, and P–R), one-way ANOVA (B and J), or two-sample Kolmogorov–Smirnov test (K and O).
Figure S4.

Expression of IL-2 by mature B cells, but not BM-localized IL-2, drives the ILC2-eosinophil circuit. (A) BM cellularity of 4–6-wk-old Cd19creRosaIL-2 mice and littermate controls. n = 9–11. (B) Frequency of eosinophils in the BM. n = 6–14. (C) Correlation between clusters in Fig. 8 D. WT:RosaIL-2 indicates whether correlation is higher or lower in WT relative to Cd19cre RosaIL-2. (D) Representative gating and frequency of myeloid progenitors (MP; lineage−Sca-1−c-kit+) cells in the BM, pregated on CD45+lineage−. n = 3. (E) Representative gating and frequency of GMPs (granulocyte-monocyte progenitors) in the BM (pregated from MP gate). n = 3. (F) Serum IL-5 in mixed WT/CD4creRosaIL-2 BM chimeras as generated in Fig. 5 A. (G) IL-5 expression among cellular lineages in the BM. n = 6–9. pDC, plasmacytoid DC. (H) Frequency of GATA3+ ILC2 among total ILCs in BM. n = 4–6. (I) Frequency of ILC2 in BM. n = 4–6. (J) Frequency of eosinophils in the BM of mice treated with anti−IL-5 neutralizing antibody. n = 3–8 mice. (K) Representative tSNE of high-parameter flow cytometry data from 4–6-wk-old CD23creRosaIL-2 mice and littermate control splenic viable cells and average frequency of each cluster per mouse. (L) Representative gating and frequency of eosinophils in spleen and BM. n = 6. SSC, side scatter. (M) Frequency of GATA3+ ILC2 among total ILCs in spleen. (N) Frequency of ILC2 in spleen. (O) Representative tSNE of high-parameter flow cytometry data from 4–6-wk-old OsxcreRosaIL-2 and control splenic viable cells and average frequency of each cluster per mouse. (P) Frequency of eosinophils in spleen and BM. n = 3. (Q) Frequency of GATA3+ ILC2 among total ILCs in spleen. (R) Frequency of ILC2 in spleen. Significance was tested by unpaired t test (A, D, E, H, I, L–N, and P–R), one-way ANOVA (B and J), or two-sample Kolmogorov–Smirnov test (K and O).

This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal